GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Zacks.com on MSN3d
Gilead Beats on Q3 Earnings and Sales, Raises Annual OutlookGilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
Considering and investment of £20k in these five FTSE 100 dividend stocks could potentially generate just over £1,600 in annual passive income.
ASHG welcomed eight 2024–2026 Human Genetics Scholars who are recognized for their accomplishments and commitment to fostering DEI in human genetics and genomics.
The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...
Mah reported receiving personal fees from GSK outside the submitted work. Hua, Hsieh, and Glen reported no relevant financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback